DOCSLIB.ORG

Board of Directors Meeting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Board of Directors Meeting BOARD OF DIRECTORS MEETING December 15, 2016 CSIS Building WASHINGTON, D.C. PERSONALIZED MEDICINE COALITION BOARD MEETING December 15, 2016 10:00 a.m. to 2:00 p.m. CSIS Building Washington, D.C. 9th Floor Turret Room Agenda Chairman’s Report 1. Approval of May 25, 2016 Minutes 2. Nominations Committee President’s Report 3. 2016 Progress Report 4. Plans for 2017 5. Finance and Budget 6. Membership 7. Public Policy 8. Science Policy 9. Communications New Business December 2016 Board Meeting Table of Contents Agenda 1. Minutes – May 25, 2016 2. Nominations • Current Board Members • Board Composition by Category • Board of Directors Duties • Bylaws 3. Progress Report • 2016 Progress Report • Conference Program (back pocket) 4. Plans for 2017 • Strategic Plan for 2017 • Clinical and Economic Value of Next-Generation Sequencing • The Personalized Medicine Education Initiative • International Comparative Landscape Analysis • Evidence for Coverage and Payment of Personalized Medicine Diagnostics • Personalized Medicine in Value Assessment Frameworks • Turning the Tide Against Cancer 2017 Conference Prospectus • CRD Proposal: Public Policy • Jen Leib Biography • PMC Vice President, Public Policy: Job Description • Kayla Smith Resume 5. Finance and Budget • 2017 Budget • Historical Budget • 2016 Sponsorships • Friends of PMC • Cash and Investments • Chart: Revenues & Expenses • Chart: Membership & Financial Performance • Chart: Cumulative Net Assets • Investment Detail 6. Membership Status • Chart: PMC Membership Numbers • Dues Schedule for Members and Sponsors • Organizations that have withdrawn from PMC since 2007 • Chart: Analysis of 2015 and 2016 Membership Non-Renewal by Reason • 2016 and 2017 New Members • Target List for 2017 Membership • List of PMC Members • Chart: PMC Membership Numbers by Category • 2016 Sponsorships 7. Public Policy • Letter to CMS on 2016 Preliminary Gapfill Payment Determinations • 2016 BIO International Convention: Personalized Medicine and Diagnostics Program Track • Letter to ICER on Non-Small Cell Lung Cancer Scoping Document • Letter to ICER on Proposed Process Improvements to Value Assessment Framework • Letter to FDA on Codevelopment • “Where We Agree When It Comes to Regulating Laboratory-Developed Diagnostics” in Personalized Medicine in Oncology 8. Science Policy • “Strategies for Integrating Personalized Medicine into Health Care Practice” (Manuscript) • Letter to FDA on Standards for Regulatory Oversight of NGS Oversight and the Use of Public Genetic Variant Databases to Support Clinical Validity for NGS-based IVDs • Policy Meeting Agenda: Envisioning the Value of Personalized Medicine (June 21, 2016) • Policy Meeting Agenda: An Update on the Precision Medicine Initiative (October 11, 2016) • Policy Meeting Agenda: PCORI & FDA in 2017 (December 7, 2016) • PMC Blog: “An Infrastructure for Innovation: How the 21st Cenury Cures Bill Could Establish a More Favorable Landscape for Personalized Medicine in 2017” • The Personalized Medicine Report 9. Communications • Impact Report • 2016 Press Releases 1. PMC to Recognize Raju Kucherlapati With 12th Annual Leadership in Personalized Medicine Award (June 29, 2016) 2. PMC Commends ICER for Extending Public Comment Period for Scope of Work in Non-Small Cell Lung Cancer (Jul 1, 2016) 3. Coalition Applauds Progress on Precision Medicine Initiative, Encourages Additional Efforts in Regulation, Reimbursement (July 7, 2016) 4. PMC Commends ‘Moonshot’ Panel for Recognizing Personalized Medicine’s Importance in Research Recommendations, Encourages Complementary Efforts From Policymakers (September 7, 2016) • 2016 Member Updates o Example • 2016 Blogs 1. Of Moonshots and Precision Medicine: Why the Time is Ripe for a National Cancer Moonshot (Kenna Shaw, Ph.D.: May 19, 2016) 2. Informed Perspectives: A Preview of the Personalized Medicine & Diagnostics Track at the 2016 BIO International Convention (Chris Wells: May 31, 2016) 3. ICER & Personalized Medicine: Time to Engage (Amy Miller, Ph.D.: June 29, 2016) 4. What ICER is Missing (Amy Miller: September 1, 2016) 5. Think the Diagnostics Community Doesn’t Agree on Anything When It Comes to LDT Regulation? Think Again. (Amy Miller: September 20, 2016) 6. Beyond the Barriers: Deconstructing the Regulatory and Reimbursement Hurdles for Companion Diagnostics (Alessandra Cesano, M.D., Ph.D.: October 3, 2016) 7. Can We Assess the Value of Personalized Medicine in Treating Cancer? (Dan Leonard, M.A.: October 19, 2016) 8. It’s Time to Protect Patient Care and Rethink the Way We Define and Assess Clinical Utility in Molecular Diagnostics (Elaine Lyon, Ph.D.: November 4, 2016) 9. A Chancellor’s Tale: Transforming Academic Medicine (Ralph Snyderman, M.D.: November 8, 2016) 10. An Infrastructure for Innovation: How the 21st Century Cures Bill Established a More Favorable Landscape for Personalized Medicine in 2017 (Daryl Pritchard, Ph.D.: December 6, 2016) 11. Advancing the Promise of Personalized Medicine With Liquid Biopsies and Analysis of ctDNA (John Beeler, Ph.D.: December 8, 2016) • Twitter Engagement: @permedcoalition • 2016 Speaking Engagements • 2016 Staff Publications • 2016 Earned Media 2016 Impact Report (spiral-bound) • 2016 Impact Report • List of Staff Publications • List of 2016 Media Mentions • Full Text of Selected Publications & Placements Supplements • Board Directory (front pocket) Finalized Publications (back pocket) • Personalized Medicine in Brief • 12th Annual Personalized Medicine Conference Program 1. Minutes – May 25, 2016 MINUTES OF THE MEETING OF THE PERSONALIZED MEDICINE COALITION BOARD OF DIRECTORS OF MAY 25, 2016 MEMBERS PRESENT: Edward Abrahams (PMC), President; Amy Abernethy (Flatiron Health), Secretary; Donna Cryer (Global Liver Institute); William Dalton (M2Gen), Chair; Neil de Crescenzo (Change Healthcare); Stephen Eck (Astellas), Vice Chair; Michael Kolodziej (Aetna); Howard McLeod (Moffitt); Michael Pellini (Foundation Medicine); Kim Popovits (Genomic Health); Lori Reilly (PhRMA); Hakan Sakul (Pfizer); Jay Wohlgemuth (Quest) OTHERS PRESENT: Amy M. Miller (PMC Executive Vice President); Daryl Pritchard (PMC Vice President, Science Policy); Faswilla Sampson (PMC Director, Operations & Secretary to the Board); Christopher Wells (PMC Director, Communications); Mary Bordoni (PMC Director, Membership & Development); David Davenport (PMC Office Administrator); Marina Polyakova (Rogers & Company Principal) A meeting of the Personalized Medicine Coalition (PMC) Board of Directors was held at the National Press Club in Washington, D.C. A quorum being present, Board Chair William Dalton called the meeting to order at 8:25 a.m. Chairman’s Report Dalton asked for and received approval of the Board meeting minutes of November 21, 2015. Finance and Budget Abrahams introduced Marina Polyakova, Principal of Rogers and Company, PMC’s outside auditor, to explain its report for 2015 (Attachment 1). She noted that PMC is financially sound, with over eight months’ cash reserves and $1.35 million in unrestricted net assets. She informed the Board that while PMC lost about $42,000 in its investment portfolio in 2015 as a result of market fluctuation, the paper loss had not had a significant impact and was in keeping with that experienced by many non- profits during 2015. She also said that PMC’s financial statements were “clean.” Her team, she said, experienced no difficulty when auditing them and confirmed that proper internal controls are in place, thanks to PMC’s careful financial management. Following the presentation of the audit, Dalton asked for and received approval of the IRS Form 990 for 2015 (Attachment 2) that all non-profits are required to file. 1 Leadership Award While there were many strong candidates, the Board identified two finalists for the 12th Annual Award for Leadership in Personalized Medicine: Raju Kucherlapati of Harvard Medical School and Ellen Sigal of Friends of Cancer Research. Kucherlapati received exalted praise and expressions of support from the Board for his work in personalized medicine, as did Ellen Sigal for her forceful leadership. In a subsequent discussion, Amy Abernethy summarized the factors that, in her view, the Board should consider when selecting the winner of the award: leadership, timing, and purpose. Donna Cryer suggested that the Board also consider who best represents PMC’s brand and mission. Jay Wohlgemuth said Kucherlapati has been the premier agent working in personalized medicine across the three areas PMC focuses on: science, business, and policy. A few members raised the concern about various recipients’ availability to accept the award at the conference. Kim Popovits encouraged the Board to consider other means of allowing recipients to accept the award (e.g. video acceptance) and not simply select recipients because they can be present at the conference. The Board unanimously selected Raju Kucherlapati as the recipient of the 2016 Leadership Award. Nominating Committee Noting their commitment to personalized medicine and to PMC, Dalton asked that the current slate of officers be re-elected and serve until the end of the year. They are Bill Dalton, Chair; Stephen Eck, Vice Chair; Stafford O’Kelly, Treasurer; and Amy Abernethy, Secretary. Regarding the growth of the Board, Dalton indicated that the Coalition should focus on securing additional representation from insurance companies, and asked Michael Kolodziej how the Coalition can best meet the needs of insurers. Kolodziej responded that asking for payers to assume a Board seat or become dues-paying
Load more

Recommended publications
  • Comment Letter
    July 23, 2008 Subject: Follow-up on July 22 Meeting Dr. Sirri et al.: I thank you for meeting with Ken Salomon, John Welborn and me yesterday afternoon to discuss Reg SHO, naked short selling and the SEC's recent emergency order. As a follow-up, I want to emphasize the following points: 1. OSTK continues to believe that it is critical that the SEC extend the pre-borrow requirement of the emergency order to the entire market, not just the 19 select companies. OSTK requests that the SEC promptly undertake swift rulemaking so that this protection applies fairly across the market. 2. OSTK continues to support the prompt and full elimination of the option market maker exception, an exception that swallows up the good intentions of Reg SHO. During yesterday's meeting, we discussed the relationship between the markets for equities and their corresponding derivatives (including listed options). You stated that options market makers enjoy an exception from the Reg SHO requirement that they locate and/or deliver shares when hedging against options positions. I am not sure that I would read Reg SHO to say that. However, under your theory, if an options market maker sells a put with a 6- month expiration, then that same market maker has the legal right to naked short and fail to deliver an equivalent amount of the underlying equity (leaving the option market maker "delta neutral”) for six months. This exception is unnecessary and open to abuse/manipulation, particularly with the married puts that often occur in Reg SHO threshold securities.
    [Show full text]
  • Advances in Optics for Biotechnology, Medicine and Surgery XV
    Program Advances in Optics for Biotechnology, Medicine and Surgery XV July 23 - 26, 2017 Westin Snowmass Snowmass Village, Colorado, USA Conference Chairs Peter So Massachusetts Institute of Technology, USA Kate Bechtel Triple Ring Technologies, USA Ivo Vellekoop University of Twente, The Netherlands Michael Choma Yale University, USA Engineering Conferences International 32 Broadway, Suite 314 - New York, NY 10004, USA www.engconfintl.org – [email protected] The Westin Snowmass Resort 100 Elbert Lane, PO Box 5009 Snowmass Village, Colorado, 81615 United States +1-970-923-8200 Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines. ECI BOARD MEMBERS Barry C. Buckland, President Mike Betenbaugh Nick Clesceri Peter Gray Michael King Raymond McCabe David Robinson Eugene Schaefer P. Somasundaran Chair of ECI Conferences Committee: Nick Clesceri ECI Technical Liaison for this conference: Brian Wilson ECI Executive Director: Barbara K. Hickernell ECI Associate Director: Kevin M. Korpics ©Engineering Conferences International Previous conferences in this series: Future Directions for Lasers in Medicine and Surgery February 26-March 3, 1989 Palm Coast, Florida Conference Chairs: Ronald W. Waynant, FDA, USA Ashley J. Welch, University of Texas-Austin, USA Future Directions for Lasers in Medicine and Surgery II February 24-March 1, 1991 Palm Coast, Florida Conference Chairs: Thomas F. Deutsch, Wellman Labs, MA General, USA Ronald W. Waynant, FDA/CDRH, USA Future Directions for Lasers in Medicine and Surgery III February 27-March 4, 1993 Palm Coast, Florida Conference Chair: Joseph T.
    [Show full text]
  • [ Emc-Lusinnufll'lergcrta'rgets
    US 20070255633Al (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2007/0255633 A1 Kridel (43) Pub. Date: NOV. 1, 2007 (54) SYSTEMS AND METHODS FOR INVESTING (52) US. Cl. ....................................................... .. 705/35 (76) Inventor: FIVJigiam J. Kridel, New York, NY (57) ABSTRACT The present invention discloses systems and methods for Correspondence Address? creating and managing ?nancial instruments and indexes PAUL’ HASTINGS’ JANOFSKY & WALKER comprised of securities for companies in subsectors of the LLP economy. These ?nancial instruments alloW investment in R0' BOX 919092 subsectors of the economy Will still being able to minimize SAN DIEGO CA 92191-9092 ’ risk by diversi?cation. The indexes serve as benchmarks for (21) App1_ NO; 11/465,768 companies in the subsectors of the economy. A procedure may be used to identify the securities to include in the (22) Filed: Allg- 18, 2006 ?nancial instruments. This procedure may include (a) iden _ _ tifying securities for companies in a sector of the economy; Related U's‘ Apphcatlon Data (b) limiting the identi?ed securities to those for companies (60) Provisional application No. 60/778,492, ?led on Mar. in a SubSeCIOr Of the SBCIOI‘ Of the economy; (0) applying 1, 2006. focus rules to further limit the identi?ed securities to those _ _ _ _ for companies Who are focused in the subsector of the Pubhcatlon Classl?catlon economy; and (d) limiting the securities included in the (51) Int, Cl, ?nancial instrument or index to those that satisfy other G06Q 40/00 (2006.01) objective criteria. ETF RULE. SET->| APPLICATION’ ' "1 _.
    [Show full text]
  • Conference Brochure
    Program Advances in Optics for Biotechnology, Medicine and Surgery XVI June 2-5, 2019 Fairmont Tremblant Mont Tremblant, Quebec, Canada Conference Co-Chairs Erin Buckley Emory University/Georgia Institute of Technology, USA Christophe Moser Polytechnique Fédérale de Lausanne (EPFL), Switzerland Brian Pogue Dartmouth College, USA David Sampson University of Surrey, United Kingdom Engineering Conferences International 32 Broadway, Suite 314 - New York, NY 10004, USA www.engconfintl.org – [email protected] Fairmont Tremblant 3045 Chemin de la Chapelle Mont-Tremblant Québec J8E 1E1 Canada Telephone: +1-819-681-7000 Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines. ECI BOARD MEMBERS Barry C. Buckland, President Mike Betenbaugh Joye Bramble Nick Clesceri Peter Gray Michael King Raymond McCabe Eugene Schaefer P. Somasundaran Chair of ECI Conferences Committee: Nick Clesceri ECI Technical Liaison for this conference: Brian Wilson ECI Executive Director: Barbara K. Hickernell ECI Associate Director: Kevin M. Korpics ©Engineering Conferences International Previous conferences in this series: Future Directions for Lasers in Medicine and Surgery February 26-March 3, 1989 Palm Coast, Florida Conference Chairs: Ronald W. Waynant, FDA, USA Ashley J. Welch, University of Texas-Austin, USA Future Directions for Lasers in Medicine and Surgery II February 24-March 1, 1991 Palm Coast, Florida Conference Chairs: Thomas F. Deutsch, Wellman Labs, MA General, USA Ronald W. Waynant, FDA/CDRH, USA Future Directions for Lasers in Medicine and Surgery III February 27-March 4, 1993 Palm Coast, Florida Conference Chair: Joseph T.
    [Show full text]
  • IPR Biotech April 2009
    WISTA APRIL 2009 From the Desk of Chairman IPR Biotechnology : Part 8 - 56 RNA splicing is the process in which introns, or intervening sequences within a gene, are removed from RNA prior to translation of RNA into protein. RNA splicing takes place in the nucleus of a cell where DNA transcription occurs. There are many types of splicing mechanisms, one of them involves the splicesome, an array of proteins that function to splice out introns. The proteins serve to initiate, stabilize, and break the RNA-RNA interactions forming during the process. The splicing pattern determines the delivery of genetic information and the nature of the final protein product. The information could be used to predict the genetic mutations potentially responsible for causing disease. The Special Feature in the current issue of WISTA:IPR Biotechnology deals with RNA splicing, its mechanism and clinical significance. It also briefly describes some of the recent patents on RNA splicing and related aspects in the field. 'On to Excellence' profiles Acrongenomics Inc, Geneva, a publicly traded research and development nanotechnology company, pioneering the development of uniquely advanced nano-molecular diagnostics for life sciences. It offers innovative and realistic concepts capable of creating viable, low cost and portable point-of-care diagnostic devices for medical testing. Arsenic is a highly toxic element and may pose health risk to humans. However, some microorganisms can tolerate relatively high concentrations of the metalloid. Researchers have found an algae that detoxifies arsenic, thus potentially discovering a possible way for cleaning up underground water, particularly in such affected areas as parts of West Bengal and Bangladesh.
    [Show full text]
  • Ripe Opportunities for Regional Collaboration in East Asia
    26 July 2001 Nature 412: 6845 (2001) © Macmillan Publishers Ltd. Ripe opportunities for regional collaboration in east 361 Asia East Asian collaboration in molecular biology could enhance the scientific viability of the region, but it requires more enthusiastic support from potential participants — particularly Japan. Back from the brink 361 The government's threat to suspend clinical trials at America's largest medical school highlights an impasse over funding. Johns Hopkins researchers fume over government 363 crackdown Drugs approval process gets speed treatment 364 Scientists fear new guidelines will stifle basic research 364 'Political fix' saves Kyoto deal from collapse 365 US rejects bioweapon inspections 365 Author of anti-encryption program faces jail 366 NASA mission has wind in its sails 366 Physicists rally behind linear-collider plan 367 Sea lions massacred in Galapagos for sex organs 367 news in brief 368 Building a biopolis 370 Having established itself as a financial and manufacturing centre, Singapore now wants to become a leading player in advanced biological research. David Cyranoski assesses the scientific ambitions of a vibrant city-state. Picture perfect 372 Medical imaging techniques are being adapted to study gene expression and other cellular activities in living animals. Corie Lok talks to the pioneers who are watching cells at work in their natural habitat. Framework welcome, but could do with fine-tuning 375 Let's get details sorted out, timescales defined, postdocs funded, entrepreneurs trained. Climate-change strategy needs to be robust 375 When three's not a crowd 375 Medicine as performance 377 JOHN HARLEY WARNER reviews Bodies Politic: Disease, Death and Doctors in Britain, 1650–1900 by Roy Porter Early British modern medicine can be considered as a type of theatre.
    [Show full text]
  • Memorandum To
    MEMORANDUM TO: File No. S7-20-08; Securities Exchange Act Release No. 58190 FROM: Division of Trading and Markets DATE: July 31, 2008 RE: Meeting on Securities Exchange Act Release No. 34-58166 On July 22, 2008, staff of the Division of Trading and Markets met with representatives from Overstock.com, Inc. to discuss Regulation SHO, “naked” short selling, and the Commission’s recent Emergency Order, (Securities Exchange Act Release No. 34- 58166). Overstock followed-up this meeting by sending an e-mail attaching a letter which is included as an attachment to this Memorandum. July 23, 2008 Subject: Follow-up on July 22 Meeting Dr. Sirri et al.: I thank you for meeting with Ken Salomon, John Welborn and me yesterday afternoon to discuss Reg SHO, naked short selling and the SEC's recent emergency order. As a follow-up, I want to emphasize the following points: 1. OSTK continues to believe that it is critical that the SEC extend the pre-borrow requirement of the emergency order to the entire market, not just the 19 select companies. OSTK requests that the SEC promptly undertake swift rulemaking so that this protection applies fairly across the market. 2. OSTK continues to support the prompt and full elimination of the option market maker exception, an exception that swallows up the good intentions of Reg SHO. During yesterday's meeting, we discussed the relationship between the markets for equities and their corresponding derivatives (including listed options). You stated that options market makers enjoy an exception from the Reg SHO requirement that they locate and/or deliver shares when hedging against options positions.
    [Show full text]
  • Sparking Economic Growth
    100 SUCCESS STORIES SPARKING ECONOMIC GROWTH How federally funded university research creates innovation, GOVERNMENT FUNDING new companies + and jobs UNIVERSITY RESEARCH = INNOVATION, COMPANIES, JOBS APRIL 2010 www.sciencecoalition.org ABOUT THIS REPORT This report was prepared by The Science Coalition (TSC) to illustrate one way in which federal investment in basic research helps to stimulate the economy. The examples highlighted were provided by the member universities of The Science Coalition (each member was invited to submit a small number of examples). They tell an important story about the role federally funded university-based research plays in the economy of the United States. The companies listed represent only a small sampling of the many companies that are the result of federally funded university-based research. This report is provided for illustrative purposes. The information about the companies was collected in 2009. The Science Coalition is a nonprofit, nonpartisan organization of more than 40 of the nation’s leading public and private research universities. It is dedi- cated to sustaining the federal government’s investment in basic research as a means to stimulate the economy, drive innovation and secure America’s global competitiveness. More information about The Science Coalition is available at www.sciencecoalition.org. The Science Coalition: Sparking Economic Growth 1 EXECUTIVE SUMMARY I The federal government is the primary source of funding for basic research conducted in the United States, providing some 60 percent of funding. The second largest source of basic research funding is the academic institutions themselves. I Universities conduct the majority of basic research in the United States — 55 percent in 2008.
    [Show full text]
  • Conference Program Peter So Massachusetts Ni Stitute of Technology, USA
    Engineering Conferences International ECI Digital Archives Advances in Optics for Biotechnology, Medicine Proceedings and Surgery XV 7-23-2017 Conference Program Peter So Massachusetts nI stitute of Technology, USA Kate Bechtel Triple Ring Technologies, USA Ivo Vellekoop University of Twente, The Netherlands Michael Choma Yale University, USA Follow this and additional works at: http://dc.engconfintl.org/biotech_med_xv Part of the Engineering Commons Recommended Citation Peter So, Kate Bechtel, Ivo Vellekoop, and Michael Choma, "Conference Program" in "Advances in Optics for Biotechnology, Medicine and Surgery XV", Peter So, Massachusetts nI stitute of Technology, USA Kate Bechtel, Triple Ring Technologies, USA Ivo Vellekoop, University of Twente, The eN therlands Michael Choma, Yale University, USA Eds, ECI Symposium Series, (2017). http://dc.engconfintl.org/biotech_med_xv/41 This Article is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Advances in Optics for Biotechnology, Medicine and Surgery XV by an authorized administrator of ECI Digital Archives. For more information, please contact [email protected]. Program Advances in Optics for Biotechnology, Medicine and Surgery XV July 23 - 26, 2017 Westin Snowmass Snowmass Village, Colorado, USA Conference Chairs Peter So Massachusetts Institute of Technology, USA Kate Bechtel Triple Ring Technologies, USA Ivo Vellekoop University of Twente, The Netherlands Michael Choma Yale University, USA Engineering Conferences International 32 Broadway, Suite 314 - New York, NY 10004, USA www.engconfintl.org – [email protected] The Westin Snowmass Resort 100 Elbert Lane, PO Box 5009 Snowmass Village, Colorado, 81615 United States +1-970-923-8200 Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.
    [Show full text]
  • Advances in Optics for Biotechnology, Medicine, and Surgery XIV
    Program Advances in Optics for Biotechnology, Medicine, and Surgery XIV June 14-17, 2015 Vail, Colorado, USA Conference Chairs Rainer Leitgeb, PhD Medical University of Vienna, Austria Richard Levenson, MD University of California – Davis, USA Laura Waller, PhD University of California, Berkeley, USA Engineering Conferences International 32 Broadway, Suite 314 - New York, NY 10004, USA Phone: 1 - 212 - 514 – 6760 www.engconfintl.org – [email protected] Vail Cascade Resort & Spa 1300 Westhaven Drive Vail, Colorado 81657 Tel: +1- 970-476-7111 Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines. ECI BOARD MEMBERS Barry C. Buckland, President Mike Betenbaugh Nick Clesceri Peter Gray Michael King Raymond McCabe David Robinson Eugene Schaefer P. Somasundaran Chair of ECI Conferences Committee: Nick Clesceri ECI Technical Liaison for this conference: Brian Wilson ECI Executive Director: Barbara K. Hickernell ECI Associate Director: Kevin M. Korpics ©Engineering Conferences International Previous conferences in this series: Future Directions for Lasers in Medicine and Surgery February 26-March 3, 1989 Palm Coast, Florida Conference Chairs: Ronald W. Waynant, FDA, USA Ashley J. Welch, University of Texas-Austin, USA Future Directions for Lasers in Medicine and Surgery II February 24-March 1, 1991 Palm Coast, Florida Conference Chairs: Thomas F. Deutsch, Wellman Labs, MA General, USA Ronald W. Waynant, FDA/CDRH, USA Future Directions for Lasers in Medicine and Surgery III February 27-March 4, 1993 Palm Coast, Florida Conference Chair: Joseph T.
    [Show full text]
  • The Commercial & Clinical Development of Pharmacogenetics
    TheFalse commercial Positive? & clinical development of pharmacogenetics Paul Martin, Graham Lewis, Andrew Smart & Andrew Webster False positive? The clinical and commercial development of pharmacogenetics Paul Martin IGBiS, University of Nottingham Graham Lewis SATSU, University of York Andy Smart Bath Spa University Andrew Webster SATSU, University of York Acknowledgements This research was supported by a Wellcome Trust Biomedical Ethics programme project award (Ref No: 018381) on The Clinical and Commercial Development of Pharmacogenetics held by Paul Martin (Principal Investigator), Alison Pilnick and Andrew Webster. The original research was carried out between 2001-03, but data in this report has been updated with data collected as part of the authors’ involvement in the following projects: 1) A study Realising the Potential of Genomic Medicine undertaken by Paul Martin and Michael Morrison funded by the Royal Pharmaceutical Society; 2) A recent ESRC Science in Society Programme project undertaken by Graham Lewis (Pharmacogenomics, diagnostic tests and clinician acceptance, Award No. RES-151-25-0049) for which he is Principal Investigator; 3) A European Commission funded report: Institute for Prospective Technological Studies (IPTS) (2005) Pharmacogenetics and Pharmacogenomics: state-of-the-art and potential socio-economic impacts in the EU. European Commission Joint Research Centre, Seville, Spain. In particular, some of the data in chapters 2 and 3 were collected as part of this work by Paul Martin and Graham Lewis. The authors would like to acknowledge the support of the following people who have helped in the management and execution of the project: Dr Alison Pilnick who was involved in establishing the project and advising on the drug case studies; Katie Coveny and Michael Morrison who helped update the industry analysis; and Martyn Pickersgill who drafted the executive summary.
    [Show full text]
  • Annotated Scholarly Guide to the HGP
    The Human Genome Project: An Annotated & Interactive Scholarly Guide to the Project in the United States Editor: Kevin Davies Cold Spring Harbor Laboratory Library & Archives The Human Genome Project: An Annotated & Interactive Scholarly Guide to the Project in the United States Editor Kevin Davies Project Leaders Ludmila Pollock Judy Wieber Production Manager Thomas Adams Contributors Brian Dick Robert Wargas Michael Eisenstein Victor McElheny Stephanie Satalino Reviewers Jan Witkowski Rick Myers Robert Cook-Deegan Acknowledgment This project was supported by the National Library of Medicine (NLM) Grants for Scholarly Works in Biomedicine and Health (G13). Project Title: Human Genome Project Documentary History: An Annotated Scholarly Guide to the HGP. PI: Ludmila Pollock Research reported in this publication was supported by the National Library of Medicine of the National Institutes of Health under Award Number G13LM011890-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Copyright © 2016 Cold Spring Harbor Laboratory. All rights reserved. Researched, compiled and published by Cold Spring Harbor Laboratory Library & Archives. All World Wide Web addresses are accurate to the best of our knowledge at the time of the printing. ISBN 978-0-9978662-0-9 Extracted: 2016-11-22 INTRODUCTION - 2 The Human Genome Project: An Annotated & Interactive Scholarly Guide to the Project in the United States 1 INTRODUCTION It is my great pleasure to introduce The Human Genome Project: An Annotated & Scholarly Guide to the Project in the United States. The idea for this annotated scholarly guide to the Human Genome Project (HGP) originated at an international meeting on the history of the HGP that was held in May of 2012 at the Cold Spring Harbor Laboratory’s Banbury Center.
    [Show full text]